New York, USA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Treg Cell-based Therapies Pipeline Landscape Analysis of 22+ Companies by DelveInsight DelveInsight’s 'Treg Cell-based Therapies Pipeline Insight 2022 ...
In a new University of California, Irvine-led study, researchers found that a certain protein prevented regulatory T cells (Tregs) from effectively doing their job in controlling the damaging effects ...
Understanding how regulatory T cells (Tregs) develop and work is key to determining how they might be manipulated to encourage the destruction of cancer cells or prevent autoimmunity. Cell behavior is ...
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced "Trix"), a biopharmaceutical company specializing in allogeneic engineered Treg and CAR-Treg cell therapies with the potential to ...
Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: Results from an investigator-initiated trial. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A ...
In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor. Colorectal cancer, however ...
Prognostic value of host genetic variants determining Bifidobacterium abundance in the lactose metabolism pathway for immunotherapy efficacy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Unlocking tumor immune evasion: IL1RL1+ Treg cells and CAFs collaborate for immunotherapy resistance
In a recent article published in the Science Advances Journal, researchers demonstrated that the crosstalk between IL1RL1+ regulatory T-cells (Treg) and cancer-associated fibroblasts (CAFs) drives the ...
In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor. Colorectal cancer, however ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results